With 0.82 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.37 million shares. The 52-week range on RNA shows that it touched its highest point at $56.00 and its lowest point at $19.24 during that stretch. It currently has a 1-year price target of $68.09. Beta for the stock currently stands at 1.01.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of RNA was down-trending over the past week, with a drop of -1.14%, but this was down by -12.66% over a month. Three-month performance dropped to -21.28% while six-month performance fell -27.38%. The stock gained 58.25% in the past year, while it has gained 4.16% so far this year. A look at the trailing 12-month EPS for RNA yields -2.90 with Next year EPS estimates of -4.55. For the next quarter, that number is -0.90. This implies an EPS growth rate of -36.99% for this year and -15.03% for next year. EPS is expected to decline by -2.64% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -34.37%.
Float and Shares Shorts:
At present, 119.89 million RNA shares are outstanding with a float of 111.07 million shares on hand for trading.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for RNA since 6 analysts follow the stock currently. There are 5 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 1 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$2.70057 being high and -$2.9885 being low. For RNA, this leads to a yearly average estimate of -$2.86936. Based on analyst estimates, the high estimate for the next quarter is -$0.59 and the low estimate is -$1.18. The average estimate for the next quarter is thus -$0.96.
